Autopsy report · NCT03257722

Pembrolizumab + Idelalisib for Lung Cancer Study

“The study was terminated due to poor accrual.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 3 years 11 months before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 2 years 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Asha Nayak

Sponsor type

University, hospital or other

Conditions

Non Small Cell Lung Cancer; Metastasis; Recurrence

Interventions

Pembrolizumab; Idelalisib

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
  “The study was terminated due to low accrual.” (97% match in meaning)
• Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension
  “Study has been terminated due to poor accrual.” (96% match in meaning)
• Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
  “Study was terminated due to poor accrual” (95% match in meaning)
• Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
  “Study terminated due to low accrual.” (94% match in meaning)
• Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
  “Study was terminated due to lack of accrual.” (94% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.